Nature Medicine, Published online: 14 April 2026; doi:10.1038/d41591-026-00020-8
A phase 1 study evaluating setidegrasib shows promising safety and clinical activity, establishing targeted protein degradation as a viable new approach for treating KRAS G12D-driven solid tumors.